Director, Portfolio Strategy

About the Company

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. The company is driven by a team of world-class professionals passionate about this mission, with core values including integrity, passion for excellence, purposeful urgency, collaboration, and commitment to people.

Summit is currently conducting multiple global Phase 3 clinical studies in oncology, including:

• Non-small Cell Lung Cancer (NSCLC):
  • HARMONi: Evaluates ivonescimab combined with chemotherapy vs. placebo plus chemotherapy in EGFR-mutated, locally advanced or metastatic non-squamous NSCLC (previously treated with a 3rd generation EGFR TKI).
  • HARMONi-3: Evaluates ivonescimab combined with chemotherapy vs. pembrolizumab combined with chemotherapy in first-line metastatic NSCLC.
  • HARMONi-7: Evaluates ivonescimab monotherapy vs. pembrolizumab monotherapy in first-line metastatic NSCLC.
• Colorectal Cancer (CRC):
  • HARMONi-GI3: Evaluates ivonescimab in combination with chemotherapy vs. bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, with additional offices in California, New Jersey, the UK, and Ireland.

About the Role

The Director, Portfolio Strategy reports to the Executive Director, Portfolio Strategy and Competitive Intelligence. This role supports strategic planning activities by providing actionable recommendations based on assessments of markets and competitors, both existing and potential.

Responsibilities

• Lead and drive New Indication strategy and planning in several Oncology indications, working cross-functionally (e.g., Clinical, Regulatory, Commercial) to guide Summit’s portfolio for late-stage clinical development strategy.
• Develop/refine framework and process for New Indication and overall portfolio strategy, providing thought leadership and supporting key strategic decision-making and investment decisions.
• Deliver strategic market and competitive intelligence insights through research, scenario planning, and impact assessments to guide executive decision-making and Summit’s portfolio strategy.
• Deliver Disease Area strategy for new solid tumor indications by providing an integrated strategy and market assessment in partnership with R&D, Clinical, Medical, Commercial, and Program teams.
• Partner with the Business Development (BD) team to provide strategic direction and guidance on business development opportunities.
• Conduct deep analysis of competitors, products, and market trends, maintaining real-time awareness of landscape changes and translating insights into strategic implications for launch and pipeline indications.
• Develop, lead, and execute comprehensive market research plans (qualitative, quantitative, and competitive), selecting vendors, designing studies, interpreting results, and ensuring timely, high-quality deliverables.
• Develop NPV, forecasting, and revenue modeling for new indications up to 18 months before launch, providing data-driven assumptions for early commercial planning.
• Lead Target Product Profile (TPP) development and alignment with cross-functional teams for several solid tumor indications.
• Integrate market research and competitive intelligence into strategic planning, including brand plans, market access, and situation analysis.
• Maintain an in-depth understanding of oncology markets and data sources, synthesizing findings into a central knowledge repository for organizational use.
• Provide ad hoc analytical support to executive stakeholders to inform R&D, commercial, and business development decisions.
• Leverage best-in-class analytical methodologies and tools to interpret epidemiology, market, and customer data into actionable recommendations.
• Build and manage external partnerships—from market research vendors to data providers—ensuring quality, accountability, and cost-effectiveness.

Requirements

• Bachelor’s degree in Biotech or a related field; advanced degree (MS, PhD) preferred.
• Minimum of 10+ years of pharmaceuticals/biotech industry experience working with both qualitative and quantitative research in oncology/pharma, with an emphasis on Non-Small Cell Lung Cancer and other Solid Tumors.
• Strong understanding of the Solid Tumor Oncology landscape, including portfolio strategy, market planning, competitive intelligence, forecasting, and key therapeutic areas such as lung cancer and colorectal cancer.
• Proven ability to identify and collect relevant market, customer, and competitor data; perform quantitative and qualitative analysis; and translate complex findings into actionable market insights and strategic recommendations.
• Experience developing and executing primary and secondary market research, with exposure to global markets preferred.
• Proven experience leading, managing, and executing end-to-end market research: designing research plans, synthesizing findings/insights, and presenting results.
• Experience with advanced spreadsheets, patient-based forecast modeling including dynamic patient models, and NPV modeling.
• Experience in facilitating competitive workshops and TPP development with program and study teams is a plus.
• Ability to use online market research tools and catalog findings to databases.
• Strong communication and presentation skills.
• Proficiency in PowerPoint, Excel, and similar data tools.
• Ability to travel up to 25% of the time, depending on business needs.

Pay

$200,000 - $250,000 USD. Actual compensation packages are based on several factors unique to each candidate, including skill set, depth of experience, certifications, and specific work location. The total compensation package may also include bonus, stock, benefits, and/or other applicable variable compensation.